$Algorhythm (RIME.US)$ Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 28, 2025, Algorhythm Holdings, Inc. (the “Company”) received a letter from the Staff of the Nasdaq Stock Market, LLC indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq L...
On November 28, 2025, Algorhythm Holdings, Inc. (the “Company”) received a letter from the Staff of the Nasdaq Stock Market, LLC indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq L...
Mangkawat
liked
$Algorhythm (RIME.US)$
SemiCab Awarded $6 Million Contract Expansion, Accelerating Projected ARR to Over $13 Million
Thursday, 11th December at 9:30 am
Largest Contract Expansion in Company's History, 10X Increase Over Initial Pilot Program
Fort Lauderdale, FL, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. ("Algorhythm") (NASDAQ: RIME) – a leading AI technology company, announced today that SemiCab has secured a major expansion of its Master Services Agreement with one of Indi...
SemiCab Awarded $6 Million Contract Expansion, Accelerating Projected ARR to Over $13 Million
Thursday, 11th December at 9:30 am
Largest Contract Expansion in Company's History, 10X Increase Over Initial Pilot Program
Fort Lauderdale, FL, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. ("Algorhythm") (NASDAQ: RIME) – a leading AI technology company, announced today that SemiCab has secured a major expansion of its Master Services Agreement with one of Indi...
1
$Pacific Mercantile Bancorp (PNBK.US)$ possible waterfall today?
$Algorhythm (RIME.US)$ possble reversal?
$Novo-Nordisk A/S (NVO.US)$
Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression
Bagsværd, Denmark, 24 November 2025 – Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease. The two trials were randomised, double-blinded, enrolled a total of 3808 adults and evaluated the efficacy and safety of oral semaglutide compared t...
Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression
Bagsværd, Denmark, 24 November 2025 – Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease. The two trials were randomised, double-blinded, enrolled a total of 3808 adults and evaluated the efficacy and safety of oral semaglutide compared t...
2
3
$Novo-Nordisk A/S (NVO.US)$ break 44 please
2
1
$SHF Holdings (SHFS.US)$ after delisting from nasdaq. what happen on nasdaq trader? it is possible waterfall. ?

![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
Mangkawat : done @DrJaguar8@Trytosaveabit